Ardelyx (ARDX)

Executive Summary

Ardelyx is a biopharmaceutical company focused on discovering and commercializing gut-targeted therapies for cardiorenal and metabolic diseases. Its approved products, XPHOZAH (tenapanor) for hyperphosphatemia in dialysis patients and IBSRELA (tenapanor) for irritable bowel syndrome with constipation, are generating commercial revenue. The company is advancing tenapanor into Phase 3 trials for cystic fibrosis and chronic idiopathic constipation, leveraging its established mechanism of action. With a market capitalization of ~$1.45B, Ardelyx is well-positioned to expand its pipeline and drive growth through new indications and potential label expansions.

Upcoming Catalysts (preview)

• TBDPhase 3 data readout for tenapanor in cystic fibrosis60% success
• TBDPhase 3 data readout for tenapanor in chronic idiopathic constipation70% success